Originally published as JCO Early Release 10.1200/JCO.2006.06.1366 on June 26 2006
Journal of Clinical Oncology, Vol 24, No 21 (July 20), 2006: pp. 3381-3387
© 2006 American Society of Clinical Oncology.
Breast-Conserving Treatment With or Without Radiotherapy in Ductal Carcinoma-In-Situ: Ten-Year Results of European Organisation for Research and Treatment of Cancer Randomized Phase III Trial 10853—A Study by the EORTC Breast Cancer Cooperative Group and EORTC Radiotherapy Group
Nina Bijker,
Philip Meijnen,
Johannes L. Peterse,
Jan Bogaerts,
Irène Van Hoorebeeck,
Jean-Pierre Julien,
Massimiliano Gennaro,
Philippe Rouanet,
Antoine Avril,
Ian S. Fentiman,
Harry Bartelink,
Emiel J. Th. Rutgers
From the Departments of Radiation Oncology, Surgery, and Pathology, Antoni van Leeuwenhoek Hospital, the Netherlands Cancer Institute, Amsterdam, the Netherlands; European Organisation for Research and Treatment of Cancer Data Center, Brussels, Belgium; Department of Surgery, Centre Henri Becquerel, Rouen; Department of Surgery, CRLC Val D'Aurelle, Montpellier; Department of Surgery, Institut Bergonié, Bordeaux, France; Department of Surgery, Istituto Nazionale dei Tumori, Milan, Italy; and the Department of Academic Oncology, Guy's Hospital, London, United Kingdom
Address reprint requests to Nina Bijker, MD, PhD, Department of Radiation Oncology, The Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX Amsterdam, the Netherlands; e-mail: n.bijker{at}nki.nl
PURPOSE: The European Organisation for Research and Treatment of Cancer conducted a randomized trial investigating the role of radiotherapy (RT) after local excision (LE) of ductal carcinoma-in-situ (DCIS) of the breast. We analyzed the efficacy of RT with 10 years follow-up on both the overall risk of local recurrence (LR) and related to clinical, histologic, and treatment factors.
PATIENTS AND METHODS: After complete LE, women with DCIS were randomly assigned to no further treatment or RT (50 Gy). One thousand ten women with mostly (71%) mammographically detected DCIS were included. The median follow-up was 10.5 years.
RESULTS: The 10-year LR-free rate was 74% in the group treated with LE alone compared with 85% in the women treated by LE plus RT (log-rank P < .0001; hazard ratio [HR] = 0.53). The risk of DCIS and invasive LR was reduced by 48% (P = .0011) and 42% (P = .0065) respectively. Both groups had similar low risks of metastases and death. At multivariate analysis, factors significantly associated with an increased LR risk were young age ( 40 years; HR = 1.89), symptomatic detection (HR = 1.55), intermediately or poorly differentiated DCIS (as opposed to well-differentiated DCIS; HR = 1.85 and HR = 1.61 respectively), cribriform or solid growth pattern (as opposed to clinging/micropapillary subtypes; HR = 2.39 and HR = 2.25 respectively), doubtful margins (HR = 1.84), and treatment by LE alone (HR = 1.82). The effect of RT was homogeneous across all assessed risk factors.
CONCLUSION: With long-term follow-up, RT after LE for DCIS continued to reduce the risk of LR, with a 47% reduction at 10 years. All patient subgroups benefited from RT.
Supported by Grants No. 2U10 CA11488-16 through 5U10 CA11488-35 from the National Cancer Institute (National Institutes of Health, Bethesda, MD).
The contents of this article are solely the responsibility of the authors and do not necessarily represent the official views of the National Cancer Institute.
Presented at the 28th Annual San Antonio Breast Cancer Symposium, San Antonio, TX, December 8-11, 2005.
Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.
Related Correspondence
- Radiation Therapy for Ductal Carcinoma In Situ: Is It Really Worth It?
Mangesh A. Thorat, Vani Parmar, Mandar S. Nadkarni, and Rajendra A. Badwe
JCO 2007 25: 461-462
[Full Text]
This article has been cited by other articles:
|
|
|
|
 
S. H. Yang, K. H. Yang, Y. P. Li, Y. C. Zhang, X. D. He, A. L. Song, J. H. Tian, L. Jiang, Z. G. Bai, L. F. He, et al.
Breast conservation therapy for stage I or stage II breast cancer: a meta-analysis of randomized controlled trials
Ann. Onc.,
June 1, 2008;
19(6):
1039 - 1044.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Holmberg, H. Garmo, B. Granstrand, A. Ringberg, L.-G. Arnesson, K. Sandelin, P. Karlsson, H. Anderson, and S. Emdin
Absolute Risk Reductions for Local Recurrence After Postoperative Radiotherapy After Sector Resection for Ductal Carcinoma In Situ of the Breast
J. Clin. Oncol.,
March 10, 2008;
26(8):
1247 - 1252.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Meijnen, H. S. A. Oldenburg, J. L. Peterse, H. Bartelink, and E. J. Th. Rutgers
Clinical Outcome after Selective Treatment of Patients Diagnosed with Ductal Carcinoma In Situ of the Breast
Ann. Surg. Oncol.,
January 1, 2008;
15(1):
235 - 243.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Dawood, K. Broglio, A. M. Gonzalez-Angulo, S.-W. Kau, W. Yang, C. Albarracin, F. Meric, G. Hortobagyi, and R. Theriault
Development of New Cancers in Patients with DCIS: The M.D. Anderson Experience
Ann. Surg. Oncol.,
January 1, 2008;
15(1):
244 - 249.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Rakovitch, J.-P. Pignol, W. Hanna, S. Narod, J. Spayne, S. Nofech-Mozes, C. Chartier, and L. Paszat
Significance of Multifocality in Ductal Carcinoma In Situ: Outcomes of Women Treated With Breast-Conserving Therapy
J. Clin. Oncol.,
December 10, 2007;
25(35):
5591 - 5596.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Meijnen and H. Bartelink
Multifocal Ductal Carcinoma In Situ of the Breast: A Contraindication for Breast-Conserving Treatment?
J. Clin. Oncol.,
December 10, 2007;
25(35):
5548 - 5549.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. C. Boughey, R. J. Gonzalez, E. Bonner, and H. M. Kuerer
Current Treatment and Clinical Trial Developments for Ductal Carcinoma In Situ of the Breast
Oncologist,
November 1, 2007;
12(11):
1276 - 1287.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Wiernikowski and E A. Mohide
Review: adequately randomised trials showed that mammography screening did not significantly reduce breast cancer, cancer, or all cause mortality but increased breast surgeries
Evid. Based Nurs.,
July 1, 2007;
10(3):
80 - 80.
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Goldhirsch, W. C. Wood, R. D. Gelber, A. S. Coates, B. Thurlimann, H. -J. Senn, and Panel Members
Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007
Ann. Onc.,
July 1, 2007;
18(7):
1133 - 1144.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. W. Pinsky, M. Rebner, L. J. Pierce, M. A. Ben-David, F. Vicini, K. A. Hunt, and M. A. Helvie
Recurrent Cancer After Breast-Conserving Surgery with Radiation Therapy for Ductal Carcinoma in Situ: Mammographic Features, Method of Detection, and Stage of Recurrence
Am. J. Roentgenol.,
July 1, 2007;
189(1):
140 - 144.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Farnie, R. B. Clarke, K. Spence, N. Pinnock, K. Brennan, N. G. Anderson, and N. J. Bundred
Novel Cell Culture Technique for Primary Ductal Carcinoma In Situ: Role of Notch and Epidermal Growth Factor Receptor Signaling Pathways
J Natl Cancer Inst,
April 18, 2007;
99(8):
616 - 627.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. A. Thorat, V. Parmar, M. S. Nadkarni, and R. A. Badwe
Radiation Therapy for Ductal Carcinoma In Situ: Is It Really Worth It?
J. Clin. Oncol.,
February 1, 2007;
25(4):
461 - 462.
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Meijnen, N. Bijker, H. Bartelink, and E. J. Th. Rutgers
In Reply
J. Clin. Oncol.,
February 1, 2007;
25(4):
462 - 462.
[Full Text]
[PDF]
|
|
|
|
|
|
|
ADDITIONAL ARTICLES ABSTRACTED IN ACP JOURNAL CLUB
Evid. Based Med.,
February 1, 2007;
12(1):
30 - 30.
[Full Text]
[PDF]
|
|
|
|
